Posted On: 06/30/2015 9:43:30 AM
Post# of 23098
$CYTR: Released 2 great news in 2 days. The one for today is a huge news:
Today:
LADR, a discovery engine designed to leverage the Company's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies. CytRx expects the LADR(TM) platform to rapidly expand its pipeline of oncology drug candidates, providing an avenue for the development of propriety drug candidates that complement its global Phase 3 aldoxorubicin program. Among the cancers being pursued are liver, pancreatic, and non-small cell lung cancer.
Yesterday:
CytRx reported interim results from its Phase 2 pilot study of Aldoxorubicin with 78% positive results and the data will be released tomorrow.
Today:
LADR, a discovery engine designed to leverage the Company's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies. CytRx expects the LADR(TM) platform to rapidly expand its pipeline of oncology drug candidates, providing an avenue for the development of propriety drug candidates that complement its global Phase 3 aldoxorubicin program. Among the cancers being pursued are liver, pancreatic, and non-small cell lung cancer.
Yesterday:
CytRx reported interim results from its Phase 2 pilot study of Aldoxorubicin with 78% positive results and the data will be released tomorrow.
(0)
(0)
